| 摘要 |
<p>The invention relates to a use of a compound of formula (I), or one of the salts thereof, wherein: R represents a linear or branched aliphatic chain selected from the group consisting of a C1-C16 saturated hydrocarbonated chain and a C2-C16 unsaturated hydrocarbonated chain, in the production of a medicament for the treatment of diseases associated with mutant lysosomal ß-galactosidase enzymes in humans.</p> |
